MX375324B - Anticuerpos contra determinantes de la superficie de s. aureus. - Google Patents

Anticuerpos contra determinantes de la superficie de s. aureus.

Info

Publication number
MX375324B
MX375324B MX2015005477A MX2015005477A MX375324B MX 375324 B MX375324 B MX 375324B MX 2015005477 A MX2015005477 A MX 2015005477A MX 2015005477 A MX2015005477 A MX 2015005477A MX 375324 B MX375324 B MX 375324B
Authority
MX
Mexico
Prior art keywords
antibodies
aureus
binding fragments
antibodies against
against surface
Prior art date
Application number
MX2015005477A
Other languages
English (en)
Spanish (es)
Other versions
MX2015005477A (es
Inventor
Bret Sellman
Chew-Shun Chang
Christine Tkaczyk
Hua Lei
Partha S Chowdhury
Peter Pavlik
Rebecca Buonpane
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2015005477A publication Critical patent/MX2015005477A/es
Publication of MX375324B publication Critical patent/MX375324B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015005477A 2012-11-06 2013-11-06 Anticuerpos contra determinantes de la superficie de s. aureus. MX375324B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US201361782405P 2013-03-14 2013-03-14
PCT/US2013/068624 WO2014074540A2 (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Publications (2)

Publication Number Publication Date
MX2015005477A MX2015005477A (es) 2015-11-30
MX375324B true MX375324B (es) 2025-03-06

Family

ID=50685304

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005477A MX375324B (es) 2012-11-06 2013-11-06 Anticuerpos contra determinantes de la superficie de s. aureus.
MX2022008079A MX2022008079A (es) 2012-11-06 2015-04-29 Anticuerpos contra determinantes de la superficie de s. aureus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008079A MX2022008079A (es) 2012-11-06 2015-04-29 Anticuerpos contra determinantes de la superficie de s. aureus.

Country Status (16)

Country Link
US (3) US9879070B2 (OSRAM)
EP (2) EP3640338A1 (OSRAM)
JP (2) JP6694269B2 (OSRAM)
KR (1) KR102288394B1 (OSRAM)
CN (2) CN109553681A (OSRAM)
AU (2) AU2013341361A1 (OSRAM)
BR (1) BR112015010125A2 (OSRAM)
CA (1) CA2890427C (OSRAM)
DK (1) DK2917360T3 (OSRAM)
ES (1) ES2776179T3 (OSRAM)
HU (1) HUE049012T2 (OSRAM)
MX (2) MX375324B (OSRAM)
PL (1) PL2917360T3 (OSRAM)
RU (1) RU2698131C2 (OSRAM)
SG (2) SG10201703678TA (OSRAM)
WO (1) WO2014074540A2 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527905B2 (en) * 2011-02-08 2016-12-27 Medimmune, Llc Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
HRP20180458T1 (hr) 2011-06-10 2018-06-29 Medimmune Limited Molekule koje vežu anti-pseudomonas psl i njihova uporaba
AU2012336028A1 (en) * 2011-11-07 2014-06-26 Medimmune, Llc Combination therapies using anti- Pseudomonas Psl and PcrV binding molecules
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
RU2661406C2 (ru) 2012-11-06 2018-07-16 МЕДИММЬЮН, ЭлЭлСи Способы лечения заболеваний, ассоциированных с s. aureus
ES2776179T3 (es) 2012-11-06 2020-07-29 Medimmune Llc Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EP3154584B1 (en) * 2014-06-03 2021-08-04 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AU2015303147A1 (en) * 2014-08-12 2017-02-23 Arsanis Biosciences Gmbh Predicting S. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
US20180179267A1 (en) * 2015-04-17 2018-06-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
CA3076632A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
WO2020023644A2 (en) * 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
AU2019359207A1 (en) 2018-10-09 2021-05-20 Humabs Biomed Sa Antibodies directed against Staphylococcus aureus leukotoxins
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
EP3923978A1 (en) 2019-02-12 2021-12-22 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
WO2020185986A1 (en) 2019-03-13 2020-09-17 Medimmune, Llc Decreasing staphylococcus aureus infections in colonized patients
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ES2372686T3 (es) * 2001-01-26 2012-01-25 Inhibitex, Inc. Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones.
US7604799B2 (en) * 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
WO2005019267A2 (en) 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
CA2638833A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
PL2244722T3 (pl) * 2008-01-31 2017-04-28 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Leczenie zakażeń drobnoustrojami
CN102089005A (zh) * 2008-05-12 2011-06-08 斯特罗克斯生物制药有限责任公司 金黄色葡萄球菌特异性抗体制剂
US8280643B2 (en) * 2008-06-30 2012-10-02 The Texas A & M University System Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof
CA2739581A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2011127032A1 (en) * 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
WO2011019423A2 (en) * 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
JP5395264B2 (ja) * 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
KR101832201B1 (ko) * 2009-07-15 2018-02-28 에임 쎄라퓨틱스 비.브이. 그람-양성 박테리아 특이적 결합 화합물
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
US9527905B2 (en) * 2011-02-08 2016-12-27 Medimmune, Llc Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
EP2744517B1 (en) * 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
PT2794905T (pt) * 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
NZ702285A (en) * 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
ES2776179T3 (es) * 2012-11-06 2020-07-29 Medimmune Llc Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
RU2661406C2 (ru) * 2012-11-06 2018-07-16 МЕДИММЬЮН, ЭлЭлСи Способы лечения заболеваний, ассоциированных с s. aureus
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
US20160235832A1 (en) * 2013-10-15 2016-08-18 The Texas A&M University System Compositions and the Use of Fibrinogen Binding Motif Presence in EFB and COA for Vaccine Against Staphylococcus Aureus and Drug Delivery
WO2015106226A2 (en) * 2014-01-10 2015-07-16 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
US9353189B2 (en) * 2014-01-24 2016-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
EP3154584B1 (en) * 2014-06-03 2021-08-04 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
US20180179267A1 (en) 2015-04-17 2018-06-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US11344615B2 (en) * 2016-07-08 2022-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells
WO2020023644A2 (en) * 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
CN113164602A (zh) * 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
AU2019359207A1 (en) * 2018-10-09 2021-05-20 Humabs Biomed Sa Antibodies directed against Staphylococcus aureus leukotoxins
WO2020185986A1 (en) * 2019-03-13 2020-09-17 Medimmune, Llc Decreasing staphylococcus aureus infections in colonized patients

Also Published As

Publication number Publication date
US20200407429A1 (en) 2020-12-31
DK2917360T3 (da) 2020-03-30
HK1215452A1 (zh) 2016-08-26
RU2698131C2 (ru) 2019-08-22
CA2890427A1 (en) 2014-05-15
RU2019122610A (ru) 2020-02-18
WO2014074540A3 (en) 2014-07-10
KR102288394B1 (ko) 2021-08-09
US11447543B2 (en) 2022-09-20
JP2019089801A (ja) 2019-06-13
AU2018241107A1 (en) 2018-10-25
CA2890427C (en) 2022-05-31
US20190016787A1 (en) 2019-01-17
KR20150094621A (ko) 2015-08-19
WO2014074540A2 (en) 2014-05-15
CN104968797B (zh) 2018-11-30
US10730934B2 (en) 2020-08-04
JP6694269B2 (ja) 2020-05-13
ES2776179T3 (es) 2020-07-29
CN109553681A (zh) 2019-04-02
MX2015005477A (es) 2015-11-30
EP3640338A1 (en) 2020-04-22
EP2917360B1 (en) 2020-01-08
JP2016507470A (ja) 2016-03-10
US20150291685A1 (en) 2015-10-15
US9879070B2 (en) 2018-01-30
HK1215054A1 (en) 2016-08-12
BR112015010125A2 (pt) 2017-08-22
SG10201703678TA (en) 2017-06-29
EP2917360A4 (en) 2017-01-25
AU2013341361A1 (en) 2015-06-04
MX2022008079A (es) 2022-07-11
AU2018241107B2 (en) 2020-09-17
EP2917360A2 (en) 2015-09-16
SG11201503232TA (en) 2015-05-28
PL2917360T3 (pl) 2020-06-29
RU2015121624A (ru) 2016-12-27
CN104968797A (zh) 2015-10-07
HUE049012T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
MX375324B (es) Anticuerpos contra determinantes de la superficie de s. aureus.
WO2015112805A8 (en) Human antibodies to pd-l1
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
PH12017500890A1 (en) Antibody drug conjugates
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
EA201790757A1 (ru) Связывающие антиген cd27l белки
EP4491195A3 (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
NZ706377A (en) Il-6 antagonists and uses thereof
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
MX2020009700A (es) Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.
WO2012135740A3 (en) Cd37-binding molecules and immunoconjugates thereof
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
MX395257B (es) Anticuerpos para cd40.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
MX2015008117A (es) Anticuerpos anti-h7cr.

Legal Events

Date Code Title Description
FG Grant or registration